MCID: CLT003
MIFTS: 64

Colitis

Categories: Gastrointestinal diseases

Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 76 29 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
ICD10 33 K52.9
MeSH 44 D003092
NCIt 50 C26723
SNOMED-CT 68 64226004
UMLS 73 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to crohn's colitis and ulcerative colitis. An important gene associated with Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Benzocaine and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 76 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1041)
# Related Disease Score Top Affiliating Genes
1 crohn's colitis 33.7 CXCL8 IFNG IL1B IL2 NOD2 TNF
2 ulcerative colitis 33.3 ABCB1 ATG16L1 CTNNB1 CXCL8 IFNG IL10
3 pouchitis 32.7 CXCL8 IL10 NOD2
4 gastroenteritis 32.5 CXCL8 IL10 IL1B IL6 TNF
5 crohn's disease 32.5 ABCB1 ATG16L1 IL10 IL10RA IL10RB IL23R
6 pyoderma gangrenosum 32.5 CXCL8 NOD2 TNF
7 inflammatory bowel disease 25, autosomal recessive 32.5 IL10 IL10RA IL10RB
8 irritable bowel syndrome 32.4 IL10 TLR9 TNF
9 colonic disease 32.2 CTNNB1 NOD2 TLR9
10 ileocolitis 31.6 MYO9B NOD2 TNF
11 ileitis 31.6 IL17A IL6 MPO NOD2 TNF
12 dengue shock syndrome 31.5 IL1B IL6 TNF
13 inflammatory bowel disease 31.3 ABCB1 ATG16L1 CXCL8 IFNG IL10 IL10RA
14 pyoderma 31.1 CXCL8 NOD2 TNF
15 cytomegalovirus infection 30.7 CXCL8 IL1B IL6 TNF
16 celiac disease 1 30.5 IFNG IL10 IL2 MYO9B TNF
17 spondyloarthropathy 1 30.4 IL17A NOD2 TNF
18 chronic granulomatous disease 30.4 IFNG IL1B MPO TLR9
19 arthritis 30.3 CXCL8 IFNG IL10 IL17A IL1B IL6
20 familial mediterranean fever 30.2 IL1B NOD2 TNF
21 esophagitis 30.2 CXCL8 IL1B IL6
22 appendicitis 30.2 CXCL8 IL10 IL1B IL6 MPO TNF
23 acute pancreatitis 30.2 CXCL8 IL10 IL6 MPO
24 fasciitis 30.1 CXCL8 IL6 TNF
25 peritonitis 30.1 CXCL8 IL10 IL1B IL6 MPO TNF
26 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.1 IFNG IL10 IL17A
27 spondylitis 30.1 IL17A IL23R IL6 NOD2 TNF
28 dermatitis 30.1 IFNG IL17A NOD2 TLR9
29 hidradenitis 30.1 IL17A NOD2 TNF
30 pneumonia 30.1 CXCL8 IL10 IL1B IL6 MPO TLR9
31 cystitis 30.1 CXCL8 IL6 TNF
32 herpes zoster 30.1 IFNG IL10 IL2
33 kawasaki disease 30.1 IL10 IL6 TNF
34 trichuriasis 30.1 CXCL8 IL10 TNF
35 hematopoietic stem cell transplantation 30.0 IFNG IL10 IL2 IL6 TNF
36 erythema multiforme 30.0 IFNG IL2 TNF
37 hidradenitis suppurativa 30.0 IL17A NOD2 TNF
38 pericarditis 30.0 IFNG IL1B IL6 TNF
39 acquired immunodeficiency syndrome 30.0 IFNG IL10 IL1B IL2 IL6 TNF
40 reactive arthritis 30.0 IFNG IL10 IL17A TNF
41 uveitis 30.0 IFNG IL10 IL17A NOD2 TNF
42 bronchiolitis obliterans 29.9 CXCL8 IFNG IL10 IL17A IL6 TNF
43 schistosomiasis 29.9 IFNG IL10 IL2 TNF
44 spondyloarthropathy 29.9 IFNG IL10 IL17A IL6 TNF
45 rheumatoid arthritis 29.9 CXCL8 IFNG IL10 IL17A IL1B IL2
46 acute generalized exanthematous pustulosis 29.9 CXCL8 IL17A
47 wells syndrome 29.9 CXCL8 IL1B IL2
48 myelitis 29.9 IL17A IL6 TNF
49 hepatitis a 29.9 IFNG IL10 TNF
50 neuritis 29.8 IFNG IL1B TNF

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO

MGI Mouse Phenotypes related to Colitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.39 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
2 digestive/alimentary MP:0005381 10.37 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
3 homeostasis/metabolism MP:0005376 10.33 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
4 cellular MP:0005384 10.32 ATG16L1 CTNNB1 IFNG IL10 IL10RA IL10RB
5 immune system MP:0005387 10.32 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
6 growth/size/body region MP:0005378 10.3 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
7 cardiovascular system MP:0005385 10.26 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL1B
8 endocrine/exocrine gland MP:0005379 10.26 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
9 mortality/aging MP:0010768 10.13 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
10 liver/biliary system MP:0005370 9.92 ABCB1 CTNNB1 IFNG IL10 IL10RB IL2
11 neoplasm MP:0002006 9.81 CTNNB1 IFNG IL10 IL1B IL2 IL23R
12 no phenotypic analysis MP:0003012 9.56 ABCB1 CTNNB1 IFNG IL10 IL17A IL2
13 respiratory system MP:0005388 9.23 CTNNB1 IFNG IL10 IL10RB IL17A IL2

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 453)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
2 tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable
3
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
4
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
5
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
6
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
7
Copper Approved, Investigational Phase 4 7440-50-8 27099
8
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6
9
leucovorin Approved Phase 4,Phase 2,Not Applicable 58-05-9 6006 143
10
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
12
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
15
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
17 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
18
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
19
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
20
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
21
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
22
Loperamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 53179-11-6 3955
23
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
24
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
25
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
26
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
27
Rifaximin Approved, Investigational Phase 4,Phase 3,Not Applicable 80621-81-4 6436173
28
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
29
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
30
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
31
Cefazolin Approved Phase 4,Phase 2,Phase 3,Not Applicable 25953-19-9 656510 33255
32
Nicotine Approved Phase 4 54-11-5 942 89594
33
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
34
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
35
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
36
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
37
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
38
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
39
Methotrexate Approved Phase 4,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
40
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
41
Magnesium citrate Approved Phase 4 3344-18-1
42
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
43
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
44
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
45
Losartan Approved Phase 4 114798-26-4 3961
46
Caffeine Approved Phase 4 58-08-2 2519
47
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3 128-13-2 31401
48
Ofloxacin Approved Phase 4 82419-36-1 4583
49
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
50
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919

Interventional clinical trials:

(show top 50) (show all 1307)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
3 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
4 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
5 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
6 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
7 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
8 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
9 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
10 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
11 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
12 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
13 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
14 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
15 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
16 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
17 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
18 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
19 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
20 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
21 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
22 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
23 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
24 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
25 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
26 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
27 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
28 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
29 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
30 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
31 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
32 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
33 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
34 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
35 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
36 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
37 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
38 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
39 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
40 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
41 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
42 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
43 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
44 Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
45 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
46 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
47 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
48 A Trial of Iron Replacement in Patients With Iron Deficiency. Completed NCT01067547 Phase 4 Iron Sucrose.;Iron sucrose
49 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease Completed NCT02162862 Phase 4 bupropion-SR
50 Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction Completed NCT01244698 Phase 4 Cefadroxil discontinued early;Cefadroxil until drain removal

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 29

Anatomical Context for Colitis

MalaCards organs/tissues related to Colitis:

41
Colon, T Cells, Neutrophil, Liver, Testes, Bone, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

19
Colon

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 8759)
# Title Authors Year
1
Toll-Like Receptor 7 Agonist-Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells. ( 30510995 )
2019
2
Clinical characterization of colitis arising from anti-PD-1 based therapy. ( 30546965 )
2019
3
Protection afforded by methanol extract of Calotropis procera latex in experimental model of colitis is mediated through inhibition of oxidative stress and pro-inflammatory signaling. ( 30551414 )
2019
4
Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance. ( 30551499 )
2019
5
NHE8 Deficiency Promotes Colitis-Associated Cancer in Mice via Expansion of Lgr5-Expressing Cells. ( 30465020 )
2019
6
Mouse Model of Colitis-Associated Colorectal Cancer (CAC): Isolation and Characterization of Mucosal-Associated Lymphoid Cells. ( 30465204 )
2019
7
Eosinophilic colitis and colonic eosinophilia. ( 30480590 )
2019
8
Preventive effect of bergenin against the development of TNBS-induced acute colitis in rats is associated with inflammatory mediators inhibition and NLRP3/ASC inflammasome signaling pathways. ( 30365937 )
2019
9
Beneficial role of Terminalia arjuna hydro-alcoholic extract in colitis and its possible mechanism. ( 30367989 )
2019
10
PPARδ agonist enhances colitis-associated colorectal cancer. ( 30391747 )
2019
11
Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes? ( 30199472 )
2019
12
Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice. ( 30205400 )
2019
13
mTOR inhibitor INK128 attenuates dextran sodium sulfate-induced colitis by promotion of MDSCs on Treg cell expansion. ( 30132862 )
2019
14
Association of T Helper 1 Cytokine Gene Single Nucleotide Polymorphisms with Ulcerative Colitis and Crohn's Disease. ( 30134230 )
2019
15
Real-World Outcomes of Vedolizumab Therapy in Ulcerative Colitis and Crohn's Disease at a Tertiary Referral Center. ( 30134234 )
2019
16
Decreased risk for microscopic colitis and inflammatory bowel disease among patients with reflux disease. ( 29603881 )
2018
17
Hypoxia-inducible factor-1 (HIF-1) activation in myeloid cells accelerates DSS-induced colitis progression in mice. ( 29967068 )
2018
18
Restoration of mucosal integrity and epithelial transport function by concomitant anti-TNFI+ treatment in chronic DSS-induced colitis. ( 29967942 )
2018
19
Microscopic colitis-microbiome, barrier function and associated diseases. ( 29610731 )
2018
20
Chemical colitis caused by hydrogen peroxide enema in a child: case report and literature review. ( 29631344 )
2018
21
How Common-and How Serious- Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. ( 29443839 )
2018
22
Microscopic colitis in Denmark and Sweden: incidence, putative risk factors, histological assessment and endoscopic activity. ( 29852792 )
2018
23
C1orf106 is a colitis risk gene that regulates stability of epithelial adherens junctions. ( 29420262 )
2018
24
Ischemic Colitis in Sickle Cell Disease: A Case Report of a Diagnostic Challenge. ( 29623225 )
2018
25
Editor's Spotlight/Take 5: How Common-and How Serious-Is Clostridium difficile Colitis After Geriatric Hip Fracture? Findings from the NSQIP Dataset. ( 29443838 )
2018
26
Histone Acetyltransferase Mof Affects the Progression of DSS-Induced Colitis. ( 29975939 )
2018
27
Evaluation by MR Enterocolonography of Lansoprazole-induced Collagenous Colitis Accompanied with Protein-losing Enteropathy. ( 29033425 )
2018
28
A Case of Pulmonary Alveolar Proteinosis with Ulcerative Colitis. ( 29709938 )
2018
29
5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis. ( 29951050 )
2018
30
Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. ( 29435325 )
2018
31
Peyer's patches-derived CD11b<sup>+</sup> B cells recruit regulatory T cells through CXCL9 in DSS-induced colitis. ( 29969845 )
2018
32
Long-Term Outcomes of Immunosuppression-NaA^ve Steroid Responders Following Hospitalization for Ulcerative Colitis. ( 29951797 )
2018
33
Efficacy of Bifidobacterium breve Fermented Milk in Maintaining Remission of Ulcerative Colitis. ( 29450747 )
2018
34
Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. ( 29370359 )
2018
35
The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. ( 29968483 )
2018
36
Dysregulated Up-Frameshift Protein 1 Promotes Ulcerative Colitis Pathogenesis Through the TNFR1-NF-I_B/MAPKs Pathway. ( 29959727 )
2018
37
The Therapeutic Effects of Adipose-Derived Stem Cells and Recombinant Peptide Pieces on Mouse Model of DSS Colitis. ( 29978718 )
2018
38
Frailty Predicts Morbidity and Mortality after Colectomy for Clostridium difficile Colitis. ( 29966560 )
2018
39
Ischemic colitis following left antegrade sclerotherapy for idiopathic varicocele. ( 29473213 )
2018
40
Gas In The Hepatic Portal Venous System Associated With Ischemic Colitis. ( 29880969 )
2018
41
Regulation of JAK2/STAT3 and NF-I_B signal transduction pathways; Veronica polita alleviates dextran sulfate sodium-induced murine colitis. ( 29448206 )
2018
42
Cytomegalovirus Colitis during Dasatinib Treatment for Patients with Hematologic Malignancy: Case Series and Literature Review. ( 29968984 )
2018
43
The regulatory role of Nrf2 in antioxidants phase2 enzymes and IL-17A expression in patients with ulcerative colitis. ( 29941222 )
2018
44
T-Bet Is Dependent on Stat-4 Inhibiting Acute Colitis but Not Stat-1 Using L4 Somatic Antigen of <i>Heligmosomoides polygyrus</i>. ( 29977172 )
2018
45
Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. ( 29928204 )
2018
46
Alterations in melatonin and serotonin signalling in the colonic mucosa of mice with dextran-sodium sulfate-induced colitis. ( 29447434 )
2018
47
The subtypes of microscopic colitis from a pathologist's perspective: past, present and future. ( 29610757 )
2018
48
New perspectives on the long-term outcome of segmental colectomy for Crohn's colitis: an observational study on 200 patients. ( 29511841 )
2018
49
Microscopic colitis: a population-based case series over a 9-year period in Northern Ireland. ( 29742325 )
2018
50
Pembrolizumab-Induced Microscopic Colitis. ( 29610496 )
2018

Variations for Colitis

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 CTNNB1 CXCL8 IFNG IL10 IL10RA IL10RB
2
Show member pathways
13.96 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
3
Show member pathways
13.78 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
4
Show member pathways
13.65 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
5
Show member pathways
13.54 CXCL8 IL10 IL10RA IL10RB IL17A IL1B
6
Show member pathways
13.49 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
7
Show member pathways
13.42 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
8
Show member pathways
13.16 CTNNB1 CXCL8